Vanta Holdings, a longevity-focused health company, supports this move as it aligns with their strategy to enter the U.S
At a glance Drug / evolocumab (Repatha), a PCSK9-inhibitor biologic antibody Supplement / glutathione (oral, liposomal, or IV forms) Known interaction / none documented in published literature or FDA label Interaction type / not applicable, no shared metabolic pathway identified Evolocumab clearance / proteolytic catabolism, not CYP450 or GSH-dependent Glutathione CYP effect / negligible at typical oral doses (250 to 1,000 mg/day) LDL-C reduction with evolocumab / up to 59% vs
User 19 ran 13 weeks for chronic multi-injury
Deficiency Biotin deficiency is relatively uncommon
Disclaimer : Glutathione IV Therapy is not intended to diagnose, treat, cure, or prevent any disease
For hair-specific applications, some practitioners inject subcutaneously near the scalp to maximize local concentration